SYDNEY: Business service provider, Honcho has developed new artificial intelligence (AI) tools aimed at simplifying the creation and launch of business websites.
This new suite of enhanced tools will make website building more accessible to start-up and small business owners who lack technical, creative, or marketing skills.
Chief Executive, Matt Abrahams said Honcho’s goal was to remove the barriers many small business owners faced when trying to establish an online presence, namely a lack of creative and technical skills.
“With Honcho, users can easily create and launch a professional website in minutes without any prior experience,” Mr Abrahams (pictured) said.
“AI streamlines the website-creation process. Users can input minimal information, often just a business name and industry, and the AI will automatically generate a customised website complete with text, images, and optimised design elements.”
He said most small business owners just wanted a fully-functioning website up and running quickly.
“Using our platform, business owners can begin marketing their business, and in turn, start adding to their bottom line, much faster,” Mr Abrahams said.
*********
Dark Horse rides to new levels
BOSTON: Dark Horse Consulting (DHC), which specialises in the field of cell and gene therapy (CGT), has acquired BioTechLogic Inc., a forerunner in technical operations, manufacturing, quality, and regulatory consulting.
DHC Chief Executive, Anthony Davies said the strategic acquisition marked a significant milestone in DHC’s growth, combining the complementary strengths of both teams.
“DHC, with operations in North America, Europe, and the Asia Pacific, is recognised for its depth of CGT expertise worldwide, while BioTechLogic has earned its stellar reputation by offering specialised consulting in process development and manufacturing, technical operations and quality systems,” Mr Davies said.
“This acquisition allows us to extend our client base into the domains of traditional biologics and vaccine development, while further optimising efficiencies of cost, timeline, and resources for our CGT customers.”
*********
BTCC calls for crypto ambassadors
VILNIUS: Crypto-currency trader, BTCC Exchange has launched its Ambassador Program, an initiative that invites crypto enthusiasts and influencers worldwide to become advocates for BTCC, helping to drive its mission and expand its reach.
In a statement, the Lithuanian-based company said the Ambassador Program consisted of four categories:
BTCC Citizens would simply promote BTCC’s online presence through likes and comments.
BTCC Creators would promote the company with original comment such as guides, reviews, and tutorials across social media.
BTCC Champions would showcase trading strategies and highlight BTCC Exchange’s key features on social media.
Finally, BTCC Connectors would organise local offline events and represent BTCC within regions.
Interested individuals can apply to multiple categories that fit their skills and experience. Ambassadors will enjoy tailored incentives, including branded merchandise, tickets to global crypto events and, in some cases, financial rewards.
*********
International scientist joins EnGeneIC board
NEW YORK: Biopharmaceutical company, EnGeneIC has appointed Daniel Von Hoff to its Scientific-Clinical Advisory Board to advise on EnGeneIC’s trial in metastatic pancreatic cancer.
Professor Von Hoff is an internationally recognised physician and scientist, currently Distinguished Professor at the Translational Genomics Research Institute (TGEN) in Phoenix, Arizona.
EnGeneIC Chief Executive, Jennifer MacDiarmid said Professor Von Hoff’s extensive knowledge and experience in pancreatic cancer, along with his clinical trial experience, would be valuable in advising on the development of the company’s oncology clinical programs.
“A pioneer and world leader in translational medicine, Professor Von Hoff’s major interest is in the development of new anticancer agents. He has been involved in more than 300 clinical studies,” Dr MacDiarmid said.
“His research at TGEN has focused on the development of therapies for patients with advanced pancreatic cancer.”
*********
Institutional investment expert joins Intech
WEST PALM BEACH: Quantitative Equity Manager, Intech has appointed Rosalind (Roz) M. Hewsenian to its Board of Directors.
Chair of Intech’s Board of Directors, Churchill Franklin said Ms Hewsenian, who recently retired as Chief Investment Officer of the Leona M. and Harry B. Helmsley Charitable Trust, brought more than 40 years of institutional investment experience to Intech during a pivotal moment in the firm’s next phase of growth.
“Roz brings a unique combination of institutional experience and strategic insight to the board,” Mr Franklin said.
“As we transition into our next phase of growth, her hands-on experience in both investing and governance will be instrumental in shaping Intech’s future.”
An occasional round-up of international business stories
No comments:
Post a Comment